THE COURSE OF ISCHEMIC HEART DISEASE IN A PATIENT WITH HEREDIC THROMBOPHILIA BASED ON A MUTATION IN THE PAI-1 GENE (CLINICAL CASE)

Authors

  • H. V. Svitlyk Danylo Halytsky Lviv National Medical University
  • V. M. Salo Danylo Halytsky Lviv National Medical University
  • M. O. Harbar Danylo Halytsky Lviv National Medical University
  • M. V. Myhovych Danylo Halytsky Lviv National Medical University
  • R. A. Kovalchuk Danylo Halytsky Lviv National Medical University
  • Yu. O. Svitlyk Danylo Halytsky Lviv National Medical University

DOI:

https://doi.org/10.11603/1811-2471.2021.v.i2.12227

Keywords:

coronary artery disease, plasminogen activator inhibitor 1, gene mutations, thrombosis, acute coronary syndrome

Abstract

Genetically determined hemostasis defects can often increase the risk of thrombotic events.

The aim – to find out the features of coronary artery disease (CHD) in a patient with a mutation in the PAI-1 gene.

Material and Methods. The course of coronary artery disease was analyzed taking into account the history, the results of laboratory tests, ECG data, echocardiography, coronary angiography.

Results. The course of coronary artery disease was characterized by frequent hospitalizations for acute coronary syndrome and steady progression of atherosclerotic changes in the coronary arteries. Dual antithrombotic therapy (rivaroxaban, 15 mg; clopidogrel, 75 mg daily) and high-intensity statin therapy reduced coronary events.

Conclusions. Diagnosing of hereditary thrombophilia and optimization of treatment strategy can improve the course of coronary artery disease.

References

Grechanina, E.Ya. (2018). Obzor mutatsyy v hene PAI [Review of mutations in the PAI gene]. Klinichna henetyka i perynatalna diahnostyka – Clinical Genetics and Perinatal Diagnostics,1 (4), 42-47 [in Russian].

Mehta, R., & Shapiro, A.D. (2008). Plasminogen activator inhibitor type 1 deficiency. Haemophilia, 14 (6), 1255-1260. DOI: https://doi.org/10.1111/j.1365-2516.2008. 01834.x

Toleuova, A.S., Tayzhanova, D.Zh., Guseinova, Z.K., & Zheksembayeva, S.O. (2013). Trombofilicheskoye sostoyaniye, obuslovlennoye mutatsiyey genov (PAI-1, MTHFR). Uspekhi sovremennogo yestestvoznaniya – Successes of Modern Natural Science, 7, 23-26 [in Russian].

Aso Y. (2007). Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front. Biosci., 12, 2957-2966. DOI: https://doi.org/10.2741/2285

Hazra, S., Stepps, V., Bhatwadekar, A.D., Caballero, S., Boulton, M.E., Higgins, P.J., & Grant, M.B. (2013). Enhancing the function of CD34 + Cells by targeting plasminogen activator inhibitor-1. PLoS One, 8 (11), e79067. DOI: https://doi.org/10.1371/journal.pone.0079067

Xu, X., Wang, H., Wang, Z., & Xiao, W. (2009). Plasminogen activator inhibitor-1 promotes inflammatory process induced by cigarette smoke extraction or lipopolysaccharides in alveolar epithelial cells. Exp. Lung Res., 35 (9), 795-805. DOI: https://doi.org/10.3109/01902140902912519

Mertens, I., Verrijken, A., Michiels, J.J., Van der Planken, M., Ruige, J.B., & Van Gaal, L.F. (2006). Among inflammation and coagulation markers, PAI-1is a true component of the metabolic syndrome. Int. J. Obes., 30 (8), 1308-1314. DOI: https://doi.org/10.1038/sj.ijo.0803189

Alessi, M.C., Poggi, M., & Juhan-Vague, I. (2007). Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr. Opin. Lipidol., 18 (3), 240-245. DOI: https://doi.org/10.1097/MOL.0b013e32814e6d29

Onalan, O., Balta, G., Oto, A., Kabakci, G., Tokgozoglu, L., Aytemir, K., & Nazli, N. (2008). Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease. J. Thromb. Thrombolysis., 26 (3), 211-217. DOI: https://doi.org/10.1007/s11239-007-0083-z

Doggen, C.J., Bertina, R.M., Cats, V.M., Reitsma, P.H., & Rosendaal, F.R. (1999). The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb. Haemost., 82 (1), 115-120.

Juhan-Vague, I., Morange, P.E., Frere, C., Aillaud, M.F., Alessi, M.C., Hawe, E., & Humphries, S.E. (2003). The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J. Thromb. Haemost., 1 (11), 2322-2329. DOI: https://doi.org/10.1046/j.1538-7836. 2003.00458.x

Böttiger, C., Koch, W., Lahn, C., Mehilli, J., von Beckerath, N., Schömig, A., & Kastrati, A. (2003). 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am. Heart J., 146 (5), 855-861. DOI: https://doi.org/10.1016/S0002-8703(03)00363-6

Parpugga, T.K., Tatarunas, V., Skipskis, V., Kupstyte, N., Zaliaduonyte-Peksiene, D., & Lesauskaite, V. (2015). The effect of PAI-1 4G/5G polymorphism and clinical factors on coronary artery occlusion in myocardial infarction. Dis. Markers, 2015, 260101. DOI: 10.1155/2015/ 260101

Ploplis, V.A. (2011). Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease. Curr. Drug Targets., 12 (12), 1782-1789. DOI: https://doi.org/10.2174/138945011797635803

Jung, R.G., Motazedian, P., Ramirez, F.D., Simard, T., Di Santo, P., Visintini, S., & Hibbert, B. (2018). Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thromb. J., 16, 12. DOI: https://doi.org/10.1186/s12959-018-0166-4

Li, Y.Y. (2012). Plasminogen activator inhibitor-1 4G/5G gene polymorphism and coronary artery disease in the Chinese Han population: a meta-analysis. PloS One, 7 (4), e33511. DOI: https://doi.org/10.1371/journal.pone. 0033511

Momot, A.P. (2013). Sostoyaniye tromboticheskoy gotovnosti – vozmozhnosti sovremennoy diagnostiki i perspektivy [The state of thrombotic readiness – the possibilities of modern diagnostics and prospects]. Meditsinskiy alfavit. Sovremennaya laboratoriya – Medical Alphabet. Modern Laboratory, 1, 20-23 [in Russian].

Pizova, N.V. (2013). Trombofilii: geneticheskiye polimorfizmy i sosudistyye katastrofy [Thrombophilia: genetic polymorphisms and vascular catastrophes]. Moscow: IMA-PRESS [in Russian].

Downloads

Published

2021-07-28

How to Cite

Svitlyk, H. V., Salo, V. M., Harbar, M. O., Myhovych, M. V., Kovalchuk, R. A., & Svitlyk, Y. O. (2021). THE COURSE OF ISCHEMIC HEART DISEASE IN A PATIENT WITH HEREDIC THROMBOPHILIA BASED ON A MUTATION IN THE PAI-1 GENE (CLINICAL CASE). Achievements of Clinical and Experimental Medicine, (2), 206–212. https://doi.org/10.11603/1811-2471.2021.v.i2.12227

Issue

No. 2 (2021)

Section

Випадок з практики

License

Copyright (c) 2021 Achievements of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.